Pharmacokinetics and 48-week Safety and Antiviral Activity of Fosamprenavir-containing Regimens in HIV-infected 2- to 18-year-old Children

BACKGROUND: Pharmacokinetics, safety and antiviral activity of twice-daily fosamprenavir with or without ritonavir were evaluated in 2- to 18-year-old protease inhibitor–naïve and -experienced HIV-1–infected children. METHODS: Serial pharmacokinetic samples were collected at week 2 and predose sampl...

Descripción completa

Detalles Bibliográficos
Autores principales: Fortuny, Claudia, Duiculescu, Dan, Cheng, Katharine, Garges, Harmony P., Cotton, Mark, Tamarirt, Desamparados Pérez, Ford, Susan L., Wire, Mary Beth, Givens, Naomi, Ross, Lisa L., Lou, Yu, Perger, Teodora, Sievers, Jörg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Williams & Wilkins 2014
Materias:
HIV Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3882305/
https://www.ncbi.nlm.nih.gov/pubmed/23811744
http://dx.doi.org/10.1097/INF.0b013e3182a1126a

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3882305/
https://www.ncbi.nlm.nih.gov/pubmed/23811744
http://dx.doi.org/10.1097/INF.0b013e3182a1126a

Ejemplares similares